10-Q: Monogram Technologies Reports Q2 2024 Results, Advances Robotic Surgery System

Monogram Technologies reported a net loss for the second quarter of 2024, while also making progress on its robotic surgery system and securing additional funding.

Summary

• Monogram Technologies, an AI-driven robotics company focused on orthopedic surgery, reported its financial results for the second quarter of 2024.
• The company experienced a net loss of $3,537,457 for the three months ended June 30, 2024, and a net loss of $7,044,161 for the six months ended June 30, 2024.
• Operating expenses decreased by 37% for the three months and 25% for the six months ended June 30, 2024, compared to the same periods in 2023, primarily due to a reduction in marketing and advertising expenses.
• Research and development expenses also decreased slightly, reflecting a shift from prototype development to validation.
• The company's cash and cash equivalents totaled $7,306,069 as of June 30, 2024.
• Monogram is pursuing FDA clearance for its mBs TKA System, having submitted a 510(k) premarket filing on July 19, 2024, with a decision expected within 90 days.
• The company has secured additional funding through a Series D Preferred Stock offering and an at-the-market common stock offering.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company is making progress on its technology and securing funding, it is still operating at a loss and faces significant risks. The sentiment is neutral to slightly negative due to the ongoing losses and dependence on external funding.

Positives

• Operating expenses decreased significantly, indicating improved cost management.
• The company has made progress in its regulatory pathway by submitting a 510(k) premarket filing to the FDA.
• Monogram has secured additional funding through new stock offerings, which will support ongoing operations and development.
• The company has a clear focus on its core technology and market opportunity.

Negatives

• The company continues to operate at a loss, with a net loss of $7,044,161 for the six months ended June 30, 2024.
• Monogram is still in the pre-revenue stage and relies on external funding to continue operations.
• The company is in discussions with Mount Sinai regarding a potential payment obligation related to a licensing agreement, which could have a material adverse effect on operations.
• The company's accumulated deficit is $58,552,825 as of June 30, 2024.

Risks

• The company's ability to continue as a going concern is dependent on its ability to raise capital and generate revenue.
• There is no guarantee that the company will obtain FDA clearance for its robotic products.
• The company is in discussions with Mount Sinai regarding a potential payment obligation, which could lead to litigation.
• The company may face challenges in establishing and maintaining supply relationships.
• The company may be impacted by inflation and other economic conditions.

Future Outlook

The company plans to continue to pursue FDA clearance for its robotic products and raise additional capital through available financing options. Management believes its current cash balances, plus the additional capital available under the Common Stock Purchase Agreement and the Series D Preferred Stock and at the market Common Stock offerings, will be sufficient for the Company to satisfy its near-term capital needs and to continue as a going concern for a reasonable period.

Management Comments

• Management believes the FDA feedback was comprehensive and will be advantageous for preparing a successful 510(k) submission.
• Management believes its current cash balances, plus the additional capital available under the Common Stock Purchase Agreement and the Series D Preferred Stock and at the market Common Stock offerings, will be sufficient for the Company to satisfy its near-term capital needs and to continue as a going concern for a reasonable period.

Industry Context

The company is operating in the growing market of robotic surgery, specifically targeting the orthopedic sector. The company believes the patent landscape for haptic control and the widespread adoption of products like Mako could be favorable for next-generation active cutting robots like Monograms mBs TKA System, which is being designed to efficiently resect bone without utilizing haptic controls.

Comparison to Industry Standards

• Monogram is developing a robotic system for knee replacement surgery, a market currently dominated by companies like Stryker with their Mako system.
• Unlike Mako, Monogram's mBs TKA System is designed to resect bone without haptic controls, which the company believes is a competitive advantage.
• The company's focus on AI and advanced machine vision aligns with the trend of increasing technological integration in medical devices.
• Monogram's financial results are typical of a pre-revenue stage medical device company, with significant R&D and regulatory expenses.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• Employees are dependent on the company's ability to secure funding and achieve commercial success.
• Customers (surgeons and patients) will benefit from the company's technology if it receives regulatory approval and is successfully commercialized.
• Suppliers and creditors are dependent on the company's financial stability.

Next Steps

• The company will continue to pursue FDA clearance for its mBs TKA System.
• The company will continue to raise capital through the Series D Preferred Stock offering and the at-the-market common stock offering.
• The company will continue discussions with Mount Sinai regarding the licensing agreement.

Key Dates

Keywords

Robotics, Orthopedic Surgery, AI, FDA Clearance, 510(k), Capital Raise, Medical Devices, mBs TKA System, Implants, Financial Results